Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
BACKGROUND
In patients with multiple endocrine neoplasia type 1 (MEN1), expression of somatostatin receptor (SST) in parathyroid adenomas and effectiveness of therapy with somatostatin analogues on primary hyperparathyroidism (PHP) have been scarcely investigated.


OBJECTIVE
To evaluate the effects of depot long acting octreotide (OCT-LAR) in patients with MEN1-related PHP.


METHODS
Eight patients with a genetically confirmed MEN1, presenting both PHP and duodeno-pancreatic neuroendocrine tumours (NET), were enrolled.


METHODS
The initial treatment was OCT-LAR 30 mg every 4 weeks. This therapy was established to stabilize the duodeno-pancreatic NET before to perform parathyroidectomy for PHP. Before OCT-LAR therapy, a SST scintigraphy was performed in all patients. SST subtype 2A immunohistochemistry was performed on parathyroid tumour samples from three patients undergone parathyroidectomy after OCT-LAR therapy.


METHODS
Serum concentrations of PTH, calcium and phosphorus as well as the 24-h urine calcium : creatinine ratio and the renal threshold phosphate concentration were evaluated before and after OCT-LAR.


RESULTS
After OCT-LAR therapy, hypercalcaemia and hypercalciuria normalized in 75% and 62.5% of patients, respectively, and serum phosphorus and renal threshold phosphate significantly increased. Serum PTH concentrations significantly decreased in all patients and normalized in two of them. SST subtype 2A immunostaining was found in all parathyroid adenomas investigated, while SST scintigraphy showed a positive parathyroid tumour uptake in three of eight patients (37.5%).


CONCLUSIONS
Six months of OCT-LAR therapy controlled hypercalcaemia and hypercalciuria in two-thirds of patients with MEN1-related PHP. Direct OCT-LAR effects mediated by binding to SST expression on parathyroid tumour cells are likely the main mechanism to explain the activity of this compound on calcium and phosphorus abnormalities in MEN1 PHP.
Faggiano
Antongiulio
A
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy. afaggian@unina.it
Tavares
Lidice Brandao
LB
Tauchmanova
Libuse
L
Milone
Francesco
F
Mansueto
Gelsomina
G
Ramundo
Valeria
V
De Caro
Maria Laura Del Basso
ML
Lombardi
Gaetano
G
De Rosa
Gaetano
G
Colao
Annamaria
A
D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000494:pharmacology; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D004379:Duodenal Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D018761:Multiple Endocrine Neoplasia Type 1 / Q000150:complications / Q000188:drug therapy*; D018358:Neuroendocrine Tumors / Q000188:drug therapy*; D015282:Octreotide / Q000008:administration & dosage* / Q000494:pharmacology; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D016105:Parathyroidectomy; D013004:Somatostatin / Q000031:analogs & derivatives; D055815:Young Adult
D018931:Antineoplastic Agents, Hormonal; D003692:Delayed-Action Preparations; D013004:Somatostatin; D015282:Octreotide